Inclisiran is a cutting-edge siRNA-based therapy that silences the PCSK9 gene in the liver, leading to dramatic and sustained reductions in LDL cholesterol. Unlike daily pills or frequent injections, Inclisiran is given just twice a year, offering unmatched convenience, better adherence, and long-term cardiovascular protection. Backed by strong clinical evidence, it’s transforming how we prevent heart attacks and strokes — making it one of the most exciting advances in lipid-lowering therapy today.